Status | Study |
Not yet recruiting |
Study Name: Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group Condition: Iron Overload Hemoglobinopathies Date: 2017-05-03 Interventions: Diagnostic Test: Continuous Glucose Monitoring (CGM) |
Completed |
Study Name: Hepatitis C Virus Infection in Patients With Hemoglobinopathies Condition: Hepatitis C, Chronic Hemoglobinopathies Date: 2017-04-14 Interventions: Drug: Antiviral drugs sofosbuvir, ribavirin, daclatasvir, ledipasvir, simeprevir, paritaprevir, dasabuvi |
Recruiting |
Study Name: Fetal Hemoglobin Induction Treatment Metformin Condition: Sickle Cell Anemia Sickle Cell Disease Date: 2016-12-01 Interventions: Drug: Metformin Subjects will be started at a dose of 500 |
Enrolling by invitation |
Study Name: Longterm Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy Condition: Beta-Thalassemia Sickle Cell Disease Date: 2015-11-30 Interventions: Other: Safety and efficacy assessments Vector copy number (VCN) measurement, safety evaluations, disease |
Recruiting |
Study Name: HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity Condition: Sickle Cell Disease Beta Thalassemia-Major Date: 2015-04-24 Interventions: Drug: alemtuzumab (Campath IH) |
Recruiting |
Study Name: Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies Condition: Sickle Cell Disease Thalassemia Date: 2015-01-21 Interventions: Biological: CordIn CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133 |
Recruiting |
Study Name: Sickle Cell Hemoglobinopathies and Bone Health Condition: Sickle Cell Disease Sickle Cell Trait Date: 2014-12-01 Interventions: Other: Healthy volunteers without SCT |
Recruiting |
Study Name: Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies Condition: Sickle Cell Disease Transfusion Dependent Alpha- or Beta- Thalassemia Date: 2014-06-27 Interventions: Drug: Reduced Toxicity Ablative Regimen |
Recruiting |
Study Name: Non-Myeloablative Conditioning and Bone Marrow Transplantation Condition: Sickle Cell Disease Hemoglobinopathies Date: 2013-05-01 Interventions: Drug: Thymoglobulin |
Completed |
Study Name: Pharmacokinetic Study of Deferiprone in Paediatric Patients Condition: Chronic Iron Overload Date: 2012-11-28 Interventions: Drug: Deferiprone, dose level 1 |